Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies.
Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies.
复制标题
DOI：
10.1002/mds.27872
复制
发表时间：
2020-01
期刊：
影响因子：
--
通讯作者：
Movement Disorder Society-Endorsed Progressive Supranuclear Palsy Study Group
中科院分区：
文献类型：
--
作者：
Respondek G;Grimm MJ;Piot I;Arzberger T;Compta Y;Englund E;Ferguson LW;Gelpi E;Roeber S;Giese A;Grossman M;Irwin DJ;Meissner WG;Nilsson C;Pantelyat A;Rajput A;van Swieten JC;Troakes C;Höglinger GU;Movement Disorder Society-Endorsed Progressive Supranuclear Palsy Study Group
运动障碍协会对进行性核上性麻痹的标准引入了“可能的4-重复（4 R）-tau蛋白病”类别，用于进行性核上性麻痹和皮质基底节变性的联合临床诊断。验证“可能的4 R-tau病变”的这些临床标准预测潜在4 R-tau病变的准确性。根据既定标准，在尸检确认的进行性核上性麻痹和皮质基底节变性（分组为4 R-tau蛋白病）以及帕金森病、多系统萎缩和额颞叶变性（分组为非4 R-tau蛋白病）患者中回顾性评估4 R-tau蛋白病的诊断准确性。我们确定了250例进行性核上性麻痹（N=195）、皮质基底节变性（N=55）和非4 R-tau蛋白病（N=161）。“可能的4 R-tau蛋白病”的敏感性和特异性在第一年为10%和99%，在最终记录时为59%和88%。新的诊断类别“可能的4 R-tau蛋白病”显示出高特异性，可能适合招募进行性核上性麻痹和皮质基底节变性患者进入靶向4 R-tau蛋白的治疗试验。
The Movement Disorder Society criteria for progressive supranuclear palsy introduced the category “probable 4-repeat (4R)-tauopathy” for joint clinical diagnosis of progressive supranuclear palsy and corticobasal degeneration. To validate the accuracy of these clinical criteria for “probable 4R-tauopathy” to predict underlying 4R-tau pathology. Diagnostic accuracy for 4R-tauopathies according to established criteria was estimated retrospectively in autopsy-confirmed patients with progressive supranuclear palsy and corticobasal degeneration (grouped as 4R-tauopathies), and Parkinson’s disease, multiple system atrophy and frontotemporal lobar degeneration (grouped as non-4R-tauopathies). We identified 250 cases with progressive supranuclear palsy (N=195), corticobasal degeneration (N=55), and with non-4R-tauopathies (N=161). Sensitivity and specificity of “probable 4R-tauopathy” was 10% and 99% in the first year and 59% and 88% at final record. The new diagnostic category “probable 4R-tauopathy” showed high specificity and may be suitable for recruitment of patients with progressive supranuclear palsy and corticobasal degeneration into therapeutic trials targeting 4R-tau.
登录
查看更多内容
DOI：
10.1016/s1474-4422(17)30157-6
发表时间：
2017-07
期刊：
The Lancet. Neurology
影响因子：
--
作者：
Boxer AL;Yu JT;Golbe LI;Litvan I;Lang AE;Höglinger GU
通讯作者：
Höglinger GU
DOI：
10.1007/s00259-018-4104-2
发表时间：
2018-12
影响因子：
9.1
作者：
Niccolini F;Wilson H;Hirschbichler S;Yousaf T;Pagano G;Whittington A;Caminiti SP;Erro R;Holton JL;Jaunmuktane Z;Esposito M;Martino D;Abdul A;Passchier J;Rabiner EA;Gunn RN;Bhatia KP;Politis M;Alzheimer’s Disease Neuroimaging Initiative
通讯作者：
Alzheimer’s Disease Neuroimaging Initiative
影响因子：
12.7
作者：
Mackenzie IR;Neumann M;Bigio EH;Cairns NJ;Alafuzoff I;Kril J;Kovacs GG;Ghetti B;Halliday G;Holm IE;Ince PG;Kamphorst W;Revesz T;Rozemuller AJ;Kumar-Singh S;Akiyama H;Baborie A;Spina S;Dickson DW;Trojanowski JQ;Mann DM
通讯作者：
Mann DM
影响因子：
14.5
作者：
Ling, Helen;O'Sullivan, Sean S.;Lees, Andrew J.
通讯作者：
Lees, Andrew J.
影响因子：
8.6
作者：
Ali, Farwa;Martin, Peter R.;Josephs, Keith A.
通讯作者：
Josephs, Keith A.